ID   TGFR2_HUMAN             Reviewed;         567 AA.
AC   P37173; B4DTV5; Q15580; Q6DKT6; Q99474;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   02-NOV-2010, entry version 134.
DE   RecName: Full=TGF-beta receptor type-2;
DE            Short=TGFR-2;
DE            EC=2.7.11.30;
DE   AltName: Full=TGF-beta type II receptor;
DE   AltName: Full=Transforming growth factor-beta receptor type II;
DE            Short=TGF-beta receptor type II;
DE            Short=TbetaR-II;
DE   Flags: Precursor;
GN   Name=TGFBR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-439.
RC   TISSUE=Liver;
RX   MEDLINE=92154690; PubMed=1310899; DOI=10.1016/0092-8674(92)90152-3;
RA   Lin H.Y., Wang X.-F., Ng-Eaton E., Weinberg R.A., Lodish H.F.;
RT   "Expression cloning of the TGF-beta type II receptor, a functional
RT   transmembrane serine/threonine kinase.";
RL   Cell 68:775-785(1992).
RN   [2]
RP   ERRATUM.
RX   PubMed=1525823;
RA   Lin H.Y., Wang X.-F., Ng-Eaton E., Weinberg R.A., Lodish H.F.;
RL   Cell 70:1069-1069(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Glial cell;
RX   MEDLINE=95047505; PubMed=7959019; DOI=10.1016/0378-1119(94)90178-3;
RA   Nikawa J.;
RT   "A cDNA encoding the human transforming growth factor beta receptor
RT   suppresses the growth defect of a yeast mutant.";
RL   Gene 149:367-372(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT ALA-439.
RX   MEDLINE=96411693; PubMed=8812462; DOI=10.1006/geno.1996.0471;
RA   Takenoshita S., Hagiwara K., Nagashima M., Gemma A., Bennett W.P.,
RA   Harris C.C.;
RT   "The genomic structure of the gene encoding the human transforming
RT   growth factor beta type II receptor (TGF-beta RII).";
RL   Genomics 36:341-344(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT ALA-439.
RX   MEDLINE=96438608; PubMed=8840968;
RA   Lu S.-L., Zhang W.C., Akiyama Y., Nomizu T., Yuasa Y.;
RT   "Genomic structure of the transforming growth factor beta type II
RT   receptor gene and its mutations in hereditary nonpolyposis colorectal
RT   cancers.";
RL   Cancer Res. 56:4595-4598(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-439.
RC   TISSUE=Liver;
RX   MEDLINE=97128789; PubMed=8973329; DOI=10.1016/S0378-1119(96)00501-X;
RA   Ogasa H., Noma T., Murata H., Kawai S., Nakazawa A.;
RT   "Cloning of a cDNA encoding the human transforming growth factor-beta
RT   type II receptor: heterogeneity of the mRNA.";
RL   Gene 181:185-190(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-36.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   PROTEIN SEQUENCE OF 23-37.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [11]
RP   INTERACTION WITH DAXX, AND MUTAGENESIS OF LYS-277.
RX   MEDLINE=21376500; PubMed=11483955; DOI=10.1038/35087019;
RA   Perlman R., Schiemann W.P., Brooks M.W., Lodish H.F., Weinberg R.A.;
RT   "TGF-beta-induced apoptosis is mediated by the adapter protein Daxx
RT   that facilitates JNK activation.";
RL   Nat. Cell Biol. 3:708-714(2001).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-548, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [13]
RP   INTERACTION WITH TCTEX1D4.
RX   PubMed=16982625; DOI=10.1074/jbc.M608614200;
RA   Meng Q.-J., Lux A., Holloschi A., Li J., Hughes J.M.X., Foerg T.,
RA   McCarthy J.E.G., Heagerty A.M., Kioschis P., Hafner M., Garland J.M.;
RT   "Identification of Tctex2beta, a novel dynein light chain family
RT   member that interacts with different transforming growth factor-beta
RT   receptors.";
RL   J. Biol. Chem. 281:37069-37080(2006).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-548, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-409; SER-548; SER-551
RP   AND SER-553, AND MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 38-159 IN COMPLEX WITH
RP   TGF-BETA3.
RX   PubMed=11850637; DOI=10.1038/nsb766;
RA   Hart P.J., Deep S., Taylor A.B., Shu Z., Hinck C.S., Hinck A.P.;
RT   "Crystal structure of the human TbetaR2 ectodomain--TGF-beta3
RT   complex.";
RL   Nat. Struct. Biol. 9:203-208(2002).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.05 ANGSTROMS) OF 49-159.
RX   PubMed=12121646; DOI=10.1016/S0969-2126(02)00780-3;
RA   Boesen C.C., Radaev S., Motyka S.A., Patamawenu A., Sun P.D.;
RT   "The 1.1 A crystal structure of human TGF-beta type II receptor ligand
RT   binding domain.";
RL   Structure 10:913-919(2002).
RN   [18]
RP   STRUCTURE BY NMR OF 38-159.
RX   PubMed=12939140; DOI=10.1021/bi034366a;
RA   Deep S., Walker K.P. III, Shu Z., Hinck A.P.;
RT   "Solution structure and backbone dynamics of the TGFbeta type II
RT   receptor extracellular domain.";
RL   Biochemistry 42:10126-10139(2003).
RN   [19]
RP   VARIANT HNPCC6 MET-315.
RX   MEDLINE=98250164; PubMed=9590282; DOI=10.1038/ng0598-17;
RA   Lu S.-L., Kawabata M., Imamura T., Akiyama Y., Nomizu T., Miyazono K.,
RA   Yuasa Y.;
RT   "HNPCC associated with germline mutation in the TGF-beta type II
RT   receptor gene.";
RL   Nat. Genet. 19:17-18(1998).
RN   [20]
RP   VARIANT ESOPHAGEAL CANCER GLN-526.
RX   MEDLINE=20248586; PubMed=10789724; DOI=10.1054/bjoc.1999.1178;
RA   Tanaka S., Mori M., Mafune K., Ohno S., Sugimachi K.;
RT   "A dominant negative mutation of transforming growth factor-beta
RT   receptor type II gene in microsatellite stable oesophageal
RT   carcinoma.";
RL   Br. J. Cancer 82:1557-1560(2000).
RN   [21]
RP   VARIANTS BREAST TUMOR MET-387; SER-435; ALA-447 AND MET-452, AND
RP   CHARACTERIZATION OF VARIANTS BREAST TUMOR SER-435; ALA-447 AND
RP   MET-452.
RX   PubMed=11212236;
RA   Luecke C.D., Philpott A., Metcalfe J.C., Thompson A.M.,
RA   Hughes-Davies L., Kemp P.R., Hesketh R.;
RT   "Inhibiting mutations in the transforming growth factor beta type 2
RT   receptor in recurrent human breast cancer.";
RL   Cancer Res. 61:482-485(2001).
RN   [22]
RP   VARIANT ILE-191.
RX   MEDLINE=22191656; PubMed=12202987; DOI=10.1007/s100380200069;
RA   Watanabe Y., Kinoshita A., Yamada T., Ohta T., Kishino T.,
RA   Matsumoto N., Ishikawa M., Niikawa N., Yoshiura K.;
RT   "A catalog of 106 single-nucleotide polymorphisms (SNPs) and 11 other
RT   types of variations in genes for transforming growth factor-beta1
RT   (TGF-beta1) and its signaling pathway.";
RL   J. Hum. Genet. 47:478-483(2002).
RN   [23]
RP   VARIANTS LDS2B PRO-308; PHE-449 AND CYS-537, AND CHARACTERIZATION OF
RP   VARIANTS LDS2B PRO-308; PHE-449 AND CYS-537.
RX   PubMed=15235604; DOI=10.1038/ng1392;
RA   Mizuguchi T., Collod-Beroud G., Akiyama T., Abifadel M., Harada N.,
RA   Morisaki T., Allard D., Varret M., Claustres M., Morisaki H.,
RA   Ihara M., Kinoshita A., Yoshiura K., Junien C., Kajii T., Jondeau G.,
RA   Ohta T., Kishino T., Furukawa Y., Nakamura Y., Niikawa N., Boileau C.,
RA   Matsumoto N.;
RT   "Heterozygous TGFBR2 mutations in Marfan syndrome.";
RL   Nat. Genet. 36:855-860(2004).
RN   [24]
RP   VARIANTS AAT3 CYS-460 AND HIS-460.
RX   PubMed=16027248; DOI=10.1161/CIRCULATIONAHA.105.537340;
RA   Pannu H., Fadulu V.T., Chang J., Lafont A., Hasham S.N., Sparks E.,
RA   Giampietro P.F., Zaleski C., Estrera A.L., Safi H.J., Shete S.,
RA   Willing M.C., Raman C.S., Milewicz D.M.;
RT   "Mutations in transforming growth factor-beta receptor type II cause
RT   familial thoracic aortic aneurysms and dissections.";
RL   Circulation 112:513-520(2005).
RN   [25]
RP   VARIANTS LDS1B ASN-336; PRO-355; TRP-357; HIS-528 AND CYS-528.
RX   PubMed=15731757; DOI=10.1038/ng1511;
RA   Loeys B.L., Chen J., Neptune E.R., Judge D.P., Podowski M., Holm T.,
RA   Meyers J., Leitch C.C., Katsanis N., Sharifi N., Xu F.L., Myers L.A.,
RA   Spevak P.J., Cameron D.E., De Backer J.F., Hellemans J., Chen Y.,
RA   Davis E.C., Webb C.L., Kress W., Coucke P.J., Rifkin D.B.,
RA   De Paepe A.M., Dietz H.C.;
RT   "A syndrome of altered cardiovascular, craniofacial, neurocognitive
RT   and skeletal development caused by mutations in TGFBR1 or TGFBR2.";
RL   Nat. Genet. 37:275-281(2005).
RN   [26]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-73 AND HIS-528.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [27]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-61; ILE-191; MET-315; TYR-328;
RP   ILE-373; MET-387 AND SER-490.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: On ligand binding, forms a receptor complex consisting
CC       of two type II and two type I transmembrane serine/threonine
CC       kinases. Type II receptors phosphorylate and activate type I
CC       receptors which autophosphorylate, then bind and activate SMAD
CC       transcriptional regulators. Receptor for TGF-beta.
CC   -!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
CC       protein] phosphate.
CC   -!- COFACTOR: Magnesium or manganese (By similarity).
CC   -!- SUBUNIT: Binds to DAXX. Interacts with TCTEX1D4.
CC   -!- INTERACTION:
CC       Q9UER7:DAXX; NbExp=1; IntAct=EBI-296151, EBI-77321;
CC       O35613:Daxx (xeno); NbExp=1; IntAct=EBI-296151, EBI-77304;
CC       P07200:TGFB1 (xeno); NbExp=1; IntAct=EBI-296151, EBI-907660;
CC       P10600:TGFB3; NbExp=1; IntAct=EBI-296151, EBI-1033020;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P37173-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P37173-2; Sequence=VSP_012157;
CC   -!- PTM: Phosphorylated on a Ser/Thr residue in the cytoplasmic
CC       domain.
CC   -!- DISEASE: Defects in TGFBR2 are the cause of hereditary non-
CC       polyposis colorectal cancer type 6 (HNPCC6) [MIM:190182].
CC       Mutations in more than one gene locus can be involved alone or in
CC       combination in the production of the HNPCC phenotype (also called
CC       Lynch syndrome). Most families with clinically recognized HNPCC
CC       have mutations in either MLH1 or MSH2 genes. HNPCC is an
CC       autosomal, dominantly inherited disease associated with marked
CC       increase in cancer susceptibility. It is characterized by a
CC       familial predisposition to early onset colorectal carcinoma (CRC)
CC       and extra-colonic cancers of the gastrointestinal, urological and
CC       female reproductive tracts. HNPCC is reported to be the most
CC       common form of inherited colorectal cancer in the Western world,
CC       and accounts for 15% of all colon cancers. Cancers in HNPCC
CC       originate within benign neoplastic polyps termed adenomas.
CC       Clinically, HNPCC is often divided into two subgroups. Type I:
CC       hereditary predisposition to colorectal cancer, a young age of
CC       onset, and carcinoma observed in the proximal colon. Type II:
CC       patients have an increased risk for cancers in certain tissues
CC       such as the uterus, ovary, breast, stomach, small intestine, skin,
CC       and larynx in addition to the colon. Diagnosis of classical HNPCC
CC       is based on the Amsterdam criteria: 3 or more relatives affected
CC       by colorectal cancer, one a first degree relative of the other
CC       two; 2 or more generation affected; 1 or more colorectal cancers
CC       presenting before 50 years of age; exclusion of hereditary
CC       polyposis syndromes. The term "suspected HNPCC" or "incomplete
CC       HNPCC" can be used to describe families who do not or only
CC       partially fulfill the Amsterdam criteria, but in whom a genetic
CC       basis for colon cancer is strongly suspected. HNPCC6 is a type of
CC       colorectal cancer complying with the clinical criteria of HNPCC,
CC       except that the onset of cancer was beyond 50 years of age in all
CC       cases.
CC   -!- DISEASE: Defects in TGFBR2 are a cause of esophageal cancer
CC       [MIM:133239].
CC   -!- DISEASE: Defects in TGFBR2 are the cause of Loeys-Dietz syndrome
CC       type 1B (LDS1B) [MIM:610168]. LDS1 is an aortic aneurysm syndrome
CC       with widespread systemic involvement. The disorder is
CC       characterized by arterial tortuosity and aneurysms,
CC       craniosynostosis, hypertelorism, and bifid uvula or cleft palate.
CC       Other findings include exotropy, micrognathia and retrognathia,
CC       structural brain abnormalities, intellectual deficit, congenital
CC       heart disease, translucent skin, joint hyperlaxity and aneurysm
CC       with dissection throughout the arterial tree.
CC   -!- DISEASE: Defects in TGFBR2 are the cause of Loeys-Dietz syndrome
CC       type 2B (LDS2B) [MIM:610380]; formerly Marfan syndrome type 2.
CC       LDS2 is an aortic aneurysm syndrome with widespread systemic
CC       involvement. Physical findings include prominent joint laxity,
CC       easy bruising, wide and atrophic scars, velvety and translucent
CC       skin with easily visible veins, spontaneous rupture of the spleen
CC       or bowel, diffuse arterial aneurysms and dissections, and
CC       catastrophic complications of pregnancy, including rupture of the
CC       gravid uterus and the arteries, either during pregnancy or in the
CC       immediate postpartum period. LDS2 is characterized by the absence
CC       of craniofacial abnormalities with the exception of bifid uvula
CC       that can be present in some patients.
CC   -!- DISEASE: Defects in TGFBR2 are the cause of aortic aneurysm
CC       familial thoracic type 3 (AAT3) [MIM:610380]. Aneurysms and
CC       dissections of the aorta usually result from degenerative changes
CC       in the aortic wall. Thoracic aortic aneurysms and dissections are
CC       primarily associated with a characteristic histologic appearance
CC       known as 'medial necrosis' or 'Erdheim cystic medial necrosis' in
CC       which there is degeneration and fragmentation of elastic fibers,
CC       loss of smooth muscle cells, and an accumulation of basophilic
CC       ground substance. AAT3 is an autosomal dominant disorder with
CC       reduced penetrance and variable expression.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/TGFBR2";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tgfbr2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M85079; AAA61164.1; -; mRNA.
DR   EMBL; D28131; BAA05673.1; -; mRNA.
DR   EMBL; U52246; AAB17553.1; -; Genomic_DNA.
DR   EMBL; U52240; AAB17553.1; JOINED; Genomic_DNA.
DR   EMBL; U52241; AAB17553.1; JOINED; Genomic_DNA.
DR   EMBL; U52242; AAB17553.1; JOINED; Genomic_DNA.
DR   EMBL; U52244; AAB17553.1; JOINED; Genomic_DNA.
DR   EMBL; U52245; AAB17553.1; JOINED; Genomic_DNA.
DR   EMBL; U69152; AAB40916.1; -; Genomic_DNA.
DR   EMBL; U69146; AAB40916.1; JOINED; Genomic_DNA.
DR   EMBL; U69147; AAB40916.1; JOINED; Genomic_DNA.
DR   EMBL; U69148; AAB40916.1; JOINED; Genomic_DNA.
DR   EMBL; U69149; AAB40916.1; JOINED; Genomic_DNA.
DR   EMBL; U69150; AAB40916.1; JOINED; Genomic_DNA.
DR   EMBL; U69151; AAB40916.1; JOINED; Genomic_DNA.
DR   EMBL; D50683; BAA09332.1; -; mRNA.
DR   EMBL; AY675319; AAT70724.1; -; Genomic_DNA.
DR   EMBL; AK300383; BAG62117.1; -; mRNA.
DR   EMBL; CH471055; EAW64412.1; -; Genomic_DNA.
DR   IPI; IPI00020431; -.
DR   IPI; IPI00164934; -.
DR   PIR; A42100; A42100.
DR   RefSeq; NP_001020018.1; -.
DR   RefSeq; NP_003233.4; -.
DR   UniGene; Hs.604277; -.
DR   UniGene; Hs.82028; -.
DR   PDB; 1KTZ; X-ray; 2.15 A; B=38-159.
DR   PDB; 1M9Z; X-ray; 1.05 A; A=50-159.
DR   PDB; 1PLO; NMR; -; A=38-159.
DR   PDB; 2PJY; X-ray; 3.00 A; B=43-149.
DR   PDB; 3KFD; X-ray; 3.00 A; E/F/G/H=38-153.
DR   PDBsum; 1KTZ; -.
DR   PDBsum; 1M9Z; -.
DR   PDBsum; 1PLO; -.
DR   PDBsum; 2PJY; -.
DR   PDBsum; 3KFD; -.
DR   ProteinModelPortal; P37173; -.
DR   SMR; P37173; 244-542.
DR   DIP; DIP-5939N; -.
DR   IntAct; P37173; 8.
DR   STRING; P37173; -.
DR   PhosphoSite; P37173; -.
DR   PRIDE; P37173; -.
DR   Ensembl; ENST00000295754; ENSP00000295754; ENSG00000163513.
DR   GeneID; 7048; -.
DR   KEGG; hsa:7048; -.
DR   NMPDR; fig|9606.3.peg.22244; -.
DR   UCSC; uc003cen.1; human.
DR   UCSC; uc003ceo.1; human.
DR   CTD; 7048; -.
DR   GeneCards; GC03P030623; -.
DR   H-InvDB; HIX0024332; -.
DR   HGNC; HGNC:11773; TGFBR2.
DR   MIM; 133239; phenotype.
DR   MIM; 190182; gene+phenotype.
DR   MIM; 610168; phenotype.
DR   MIM; 610380; phenotype.
DR   Orphanet; 60030; Aortic aneurysm syndrome, Loeys-Dietz type.
DR   Orphanet; 88636; Aortic dilatation - joint hypermobility - arterial tortuosity.
DR   Orphanet; 144; Familial nonpolyposis colon cancer.
DR   Orphanet; 91387; Familial thoracic aortic aneurysm.
DR   Orphanet; 558; Marfan syndrome.
DR   PharmGKB; PA36486; -.
DR   HOVERGEN; HBG104975; -.
DR   OMA; MVTDNNG; -.
DR   OrthoDB; EOG9QRKPF; -.
DR   PhylomeDB; P37173; -.
DR   BRENDA; 2.7.10.2; 247.
DR   BRENDA; 2.7.11.30; 247.
DR   Pathway_Interaction_DB; glypican_1pathway; Glypican 1 network.
DR   Pathway_Interaction_DB; avb3_integrin_pathway; Integrins in angiogenesis.
DR   Pathway_Interaction_DB; tgfbrpathway; TGF-beta receptor signaling.
DR   Reactome; REACT_6844; Signaling by TGF beta.
DR   NextBio; 27541; -.
DR   ArrayExpress; P37173; -.
DR   Bgee; P37173; -.
DR   CleanEx; HS_TGFBR2; -.
DR   Genevestigator; P37173; -.
DR   GermOnline; ENSG00000163513; Homo sapiens.
DR   GO; GO:0005901; C:caveola; IDA:BHF-UCL.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0070022; C:transforming growth factor beta receptor co...; IC:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005539; F:glycosaminoglycan binding; IDA:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:BHF-UCL.
DR   GO; GO:0046332; F:SMAD binding; IDA:BHF-UCL.
DR   GO; GO:0050431; F:transforming growth factor beta binding; IDA:BHF-UCL.
DR   GO; GO:0005026; F:transforming growth factor beta receptor ac...; IEA:InterPro.
DR   GO; GO:0034713; F:type I transforming growth factor beta rece...; IDA:BHF-UCL.
DR   GO; GO:0034713; F:type I transforming growth factor beta rece...; IPI:BHF-UCL.
DR   GO; GO:0034714; F:type III transforming growth factor beta re...; IDA:BHF-UCL.
DR   GO; GO:0032147; P:activation of protein kinase activity; ISS:BHF-UCL.
DR   GO; GO:0007420; P:brain development; ISS:BHF-UCL.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0035162; P:embryonic hemopoiesis; ISS:BHF-UCL.
DR   GO; GO:0007507; P:heart development; ISS:BHF-UCL.
DR   GO; GO:0043011; P:myeloid dendritic cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0060021; P:palate development; ISS:BHF-UCL.
DR   GO; GO:0060389; P:pathway-restricted SMAD protein phosphoryla...; IDA:BHF-UCL.
DR   GO; GO:0001569; P:patterning of blood vessels; ISS:BHF-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0002663; P:positive regulation of B cell tolerance ind...; ISS:BHF-UCL.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell pro...; ISS:BHF-UCL.
DR   GO; GO:0051138; P:positive regulation of NK T cell differenti...; ISS:BHF-UCL.
DR   GO; GO:0002666; P:positive regulation of T cell tolerance ind...; ISS:BHF-UCL.
DR   GO; GO:0002651; P:positive regulation of tolerance induction ...; ISS:BHF-UCL.
DR   GO; GO:0070723; P:response to cholesterol; IDA:BHF-UCL.
DR   GO; GO:0042493; P:response to drug; IDA:BHF-UCL.
DR   GO; GO:0007179; P:transforming growth factor beta receptor si...; IDA:BHF-UCL.
DR   GO; GO:0007179; P:transforming growth factor beta receptor si...; IMP:BHF-UCL.
DR   GO; GO:0001570; P:vasculogenesis; ISS:BHF-UCL.
DR   InterPro; IPR000333; Activin_II_recpt.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR015769; TGF-beta-2_rcpt_C.
DR   InterPro; IPR017194; Transform_growth_fac-b_typ-2.
DR   InterPro; IPR015013; Transforming_GF_b_rcpt_2_ecto.
DR   PANTHER; PTHR23255:SF11; TGF-beta_II_C; 1.
DR   Pfam; PF08917; ecTbetaR2; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   PIRSF; PIRSF037393; TGFRII; 1.
DR   PRINTS; PR00653; ACTIVIN2R.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Aortic aneurysm; ATP-binding;
KW   Chromosomal rearrangement; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Hereditary nonpolyposis colorectal cancer; Kinase;
KW   Magnesium; Manganese; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Receptor;
KW   Serine/threonine-protein kinase; Signal; Transferase; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     22
FT   CHAIN        23    567       TGF-beta receptor type-2.
FT                                /FTId=PRO_0000024426.
FT   TOPO_DOM     23    166       Extracellular (Potential).
FT   TRANSMEM    167    187       Helical; (Potential).
FT   TOPO_DOM    188    567       Cytoplasmic (Potential).
FT   DOMAIN      244    544       Protein kinase.
FT   NP_BIND     250    258       ATP (By similarity).
FT   ACT_SITE    379    379       Proton acceptor (By similarity).
FT   BINDING     277    277       ATP (By similarity).
FT   MOD_RES     409    409       Phosphoserine.
FT   MOD_RES     548    548       Phosphoserine.
FT   MOD_RES     551    551       Phosphoserine.
FT   MOD_RES     553    553       Phosphoserine.
FT   CARBOHYD     70     70       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     94     94       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    154    154       N-linked (GlcNAc...) (Potential).
FT   DISULFID     51     84
FT   DISULFID     54     71
FT   DISULFID     61     67
FT   DISULFID     77    101
FT   DISULFID    121    136
FT   DISULFID    138    143
FT   VAR_SEQ      31     32       SV -> SDVEMEAQKDEIICPSCNRTAHPLRHI (in
FT                                isoform 2).
FT                                /FTId=VSP_012157.
FT   VARIANT      36     36       M -> V (in dbSNP:rs17025864).
FT                                /FTId=VAR_020510.
FT   VARIANT      61     61       C -> R (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041414.
FT   VARIANT      73     73       I -> V (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_036070.
FT   VARIANT     191    191       V -> I (in dbSNP:rs56105708).
FT                                /FTId=VAR_017606.
FT   VARIANT     308    308       L -> P (in LDS2B; has a negative effect
FT                                on TGF-beta signaling; dbSNP:rs28934568).
FT                                /FTId=VAR_022351.
FT   VARIANT     315    315       T -> M (in HNPCC6; dbSNP:rs34833812).
FT                                /FTId=VAR_008156.
FT   VARIANT     328    328       H -> Y (in a lung neuroendocrine
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_041415.
FT   VARIANT     336    336       Y -> N (in LDS1B).
FT                                /FTId=VAR_022352.
FT   VARIANT     355    355       A -> P (in LDS1B).
FT                                /FTId=VAR_022353.
FT   VARIANT     357    357       G -> W (in LDS1B).
FT                                /FTId=VAR_022354.
FT   VARIANT     373    373       M -> I (in dbSNP:rs35719192).
FT                                /FTId=VAR_041416.
FT   VARIANT     387    387       V -> M (in a breast tumor;
FT                                dbSNP:rs35766612).
FT                                /FTId=VAR_022355.
FT   VARIANT     435    435       N -> S (in a breast tumor; signaling of
FT                                TGF-beta significantly inhibited).
FT                                /FTId=VAR_022356.
FT   VARIANT     439    439       V -> A (in dbSNP:rs1050833).
FT                                /FTId=VAR_028063.
FT   VARIANT     447    447       V -> A (in a breast tumor; signaling of
FT                                TGF-beta significantly inhibited).
FT                                /FTId=VAR_022357.
FT   VARIANT     449    449       S -> F (in LDS2B; has a negative effect
FT                                on TGF-beta signaling).
FT                                /FTId=VAR_022358.
FT   VARIANT     452    452       L -> M (in a breast tumor; signaling of
FT                                TGF-beta significantly inhibited).
FT                                /FTId=VAR_022359.
FT   VARIANT     460    460       R -> C (in AAT3).
FT                                /FTId=VAR_029760.
FT   VARIANT     460    460       R -> H (in AAT3).
FT                                /FTId=VAR_029761.
FT   VARIANT     490    490       N -> S (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041417.
FT   VARIANT     526    526       E -> Q (in esophageal cancer).
FT                                /FTId=VAR_015816.
FT   VARIANT     528    528       R -> C (in LDS1B).
FT                                /FTId=VAR_022360.
FT   VARIANT     528    528       R -> H (in LDS1B).
FT                                /FTId=VAR_022361.
FT   VARIANT     537    537       R -> C (in LDS2B; has a negative effect
FT                                on TGF-beta signaling; dbSNP:rs28934869).
FT                                /FTId=VAR_022362.
FT   MUTAGEN     277    277       K->R: Abolishes kinase activity, TGF-beta
FT                                signaling and interaction with DAXX.
FT   CONFLICT    381    381       K -> N (in Ref. 6; BAA09332).
FT   STRAND       50     52
FT   STRAND       55     58
FT   STRAND       65     68
FT   STRAND       74     76
FT   STRAND       83     90
FT   STRAND       95    102
FT   TURN        114    117
FT   STRAND      119    122
FT   STRAND      124    126
FT   STRAND      131    138
FT   HELIX       143    145
FT   STRAND      146    148
SQ   SEQUENCE   567 AA;  64568 MW;  C541DA751FFBDBEB CRC64;
     MGRGLLRGLW PLHIVLWTRI ASTIPPHVQK SVNNDMIVTD NNGAVKFPQL CKFCDVRFST
     CDNQKSCMSN CSITSICEKP QEVCVAVWRK NDENITLETV CHDPKLPYHD FILEDAASPK
     CIMKEKKKPG ETFFMCSCSS DECNDNIIFS EEYNTSNPDL LLVIFQVTGI SLLPPLGVAI
     SVIIIFYCYR VNRQQKLSST WETGKTRKLM EFSEHCAIIL EDDRSDISST CANNINHNTE
     LLPIELDTLV GKGRFAEVYK AKLKQNTSEQ FETVAVKIFP YEEYASWKTE KDIFSDINLK
     HENILQFLTA EERKTELGKQ YWLITAFHAK GNLQEYLTRH VISWEDLRKL GSSLARGIAH
     LHSDHTPCGR PKMPIVHRDL KSSNILVKND LTCCLCDFGL SLRLDPTLSV DDLANSGQVG
     TARYMAPEVL ESRMNLENVE SFKQTDVYSM ALVLWEMTSR CNAVGEVKDY EPPFGSKVRE
     HPCVESMKDN VLRDRGRPEI PSFWLNHQGI QMVCETLTEC WDHDPEARLT AQCVAERFSE
     LEHLDRLSGR SCSEEKIPED GSLNTTK
//
